GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Stratec SE (OTCPK:SBMDY) » Definitions » ROE % Adjusted to Book Value

Stratec SE (Stratec SE) ROE % Adjusted to Book Value : 0.00% (As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Stratec SE ROE % Adjusted to Book Value?

Stratec SE's ROE % for the quarter that ended in Mar. 2024 was 0.77%. Stratec SE's PB Ratio for the quarter that ended in Mar. 2024 was N/A. Stratec SE's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 was N/A.


Stratec SE ROE % Adjusted to Book Value Historical Data

The historical data trend for Stratec SE's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stratec SE ROE % Adjusted to Book Value Chart

Stratec SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Stratec SE Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Stratec SE's ROE % Adjusted to Book Value

For the Medical Devices subindustry, Stratec SE's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Stratec SE's ROE % Adjusted to Book Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Stratec SE's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Stratec SE's ROE % Adjusted to Book Value falls into.



Stratec SE ROE % Adjusted to Book Value Calculation

Stratec SE's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=5.78% / N/A
=N/A

Stratec SE's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.77% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Stratec SE ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Stratec SE's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Stratec SE (Stratec SE) Business Description

Traded in Other Exchanges
Address
Gewerbestrasse 37, Birkenfeld, RP, DEU, 75217
Stratec SE designs and manufactures automated analyzer systems for laboratory data management and solutions for molecular diagnostic sample preparation and stabilization. Its business segments are Instrumentation, Diatron and Smart Consumables. Its Instrumentation segment is engaged in designing and manufacturing automated analyzer systems for clinical diagnostics and biotechnology customers. The Diatron segment comprises the business with systems, system components, consumables, and tests in the low throughput hematology and clinical chemistry segment. Its Smart Consumables segment is engaged in developing and selling scientific materials, such as nucleic acid purification. The company generates maximum revenue from the Instrumentation segment.

Stratec SE (Stratec SE) Headlines

From GuruFocus